Artwork

No Silver Bullet 4 PD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 No Silver Bullet 4 PD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Parkinson's Disease:- Prof Tom Foltynie "Does the repurposing of diabetes drugs offer hope for PD"

1:20:45
 
공유
 

Manage episode 334467168 series 3371816
No Silver Bullet 4 PD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 No Silver Bullet 4 PD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

An excellent presentation from Prof Tom Foltynie followed by an examining Q &A session from the audience, probing further into the benefits of these drugs, giving real-time trial updates and some testimony from some PwP actually on the trial giving us a real insight.
Professor Tom Foltynie is Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology & Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London.
He is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa.
He is chief investigator for a series of trials of Exenatide- a potential neurorestorative treatment for PD, as well as the lead clinician at UCL for trials of alpha-synuclein vaccination for PD and Oxford Biomedica/ Axovant’s gene therapy product for PD, and the Transeuro PD cell transplantation program.
You can follow Prof Foltynie on Twitter https://twitter.com/foltynie
You can find out more from Prof Foltynie here:-
https://www.ucl.ac.uk/ion/research/ou...
https://www.uclh.nhs.uk/our-services/...
https://www.michaeljfox.org/researche...
https://www.youtube.com/watch?v=WozwO...
Want alerts for future speaker sessions?
Email us at nosilverbullet4pd@gmail.com
You can follow us on social media
Instagram:- https://www.instagram.com/nosilverbul...
Twitter:- https://twitter.com/NSB4PD

  continue reading

29 에피소드

Artwork
icon공유
 
Manage episode 334467168 series 3371816
No Silver Bullet 4 PD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 No Silver Bullet 4 PD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

An excellent presentation from Prof Tom Foltynie followed by an examining Q &A session from the audience, probing further into the benefits of these drugs, giving real-time trial updates and some testimony from some PwP actually on the trial giving us a real insight.
Professor Tom Foltynie is Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology & Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London.
He is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa.
He is chief investigator for a series of trials of Exenatide- a potential neurorestorative treatment for PD, as well as the lead clinician at UCL for trials of alpha-synuclein vaccination for PD and Oxford Biomedica/ Axovant’s gene therapy product for PD, and the Transeuro PD cell transplantation program.
You can follow Prof Foltynie on Twitter https://twitter.com/foltynie
You can find out more from Prof Foltynie here:-
https://www.ucl.ac.uk/ion/research/ou...
https://www.uclh.nhs.uk/our-services/...
https://www.michaeljfox.org/researche...
https://www.youtube.com/watch?v=WozwO...
Want alerts for future speaker sessions?
Email us at nosilverbullet4pd@gmail.com
You can follow us on social media
Instagram:- https://www.instagram.com/nosilverbul...
Twitter:- https://twitter.com/NSB4PD

  continue reading

29 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드